A new approach to a growing cancer problem is in the works. Anbogen Therapeutics has announced that the U.S. Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for Phase I/II clinical trials of its ABT-301 in combination with anti-PD-1 antibody tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC). The study targets the majority of patients, who have poor responses to immunotherapy, and thus aims to provide a novel treatment option for this unmet clinical need.

Immune checkpoint inhibitors (ICIs) have emerged as a primary treatment for mCRC with mismatch repair deficiency or high microsatellite instability. However, only a small fraction of patients benefit, as less than five percent of mCRC cases exhibit these cha

See Full Page